Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT ID: NCT00154401
Last Updated: 2017-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
177 participants
INTERVENTIONAL
2005-01-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00318422
Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes
NCT01288326
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00331851
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
NCT01484262
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
NCT01509755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liraglutide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diet treated subjects: 7.5% \< HbA1c \< 10%
* Single oral drug therapy subjects: 7.0% \< HbA1c \< 9.5%
* Body Mass Index (BMI): max 40 kg/m\^2
Exclusion Criteria
* Subjects with any serious medical conditions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Aalborg, , Denmark
Novo Nordisk Investigational Site
Århus C, , Denmark
Novo Nordisk Investigational Site
Copenhagen, , Denmark
Novo Nordisk Investigational Site
Hellerup, , Denmark
Novo Nordisk Investigational Site
Hvidovre, , Denmark
Novo Nordisk Investigational Site
Kolding, , Denmark
Novo Nordisk Investigational Site
København S, , Denmark
Novo Nordisk Investigational Site
Køge, , Denmark
Novo Nordisk Investigational Site
Antibes, , France
Novo Nordisk Investigational Site
Dax, , France
Novo Nordisk Investigational Site
La Rochelle, , France
Novo Nordisk Investigational Site
Marseille, , France
Novo Nordisk Investigational Site
Montpellier, , France
Novo Nordisk Investigational Site
Mougins, , France
Novo Nordisk Investigational Site
Narbonne, , France
Novo Nordisk Investigational Site
Nevers, , France
Novo Nordisk Investigational Site
Nîmes, , France
Novo Nordisk Investigational Site
Pessac, , France
Novo Nordisk Investigational Site
Rennes, , France
Novo Nordisk Investigational Site
Vénissieux, , France
Novo Nordisk Investigational Site
's-Hertogenbosch, , Netherlands
Novo Nordisk Investigational Site
Amsterdam, , Netherlands
Novo Nordisk Investigational Site
Apeldoorn, , Netherlands
Novo Nordisk Investigational Site
Groningen, , Netherlands
Novo Nordisk Investigational Site
Hengelo, , Netherlands
Novo Nordisk Investigational Site
Sliedrecht, , Netherlands
Novo Nordisk Investigational Site
The Hague, , Netherlands
Novo Nordisk Investigational Site
Banská Bystrica, , Slovakia
Novo Nordisk Investigational Site
Bratislava, , Slovakia
Novo Nordisk Investigational Site
Bratislava, , Slovakia
Novo Nordisk Investigational Site
Bratislava, , Slovakia
Novo Nordisk Investigational Site
Bratislava, , Slovakia
Novo Nordisk Investigational Site
Košice, , Slovakia
Novo Nordisk Investigational Site
Košice, , Slovakia
Novo Nordisk Investigational Site
Košice, , Slovakia
Novo Nordisk Investigational Site
Lučenec, , Slovakia
Novo Nordisk Investigational Site
Prešov, , Slovakia
Novo Nordisk Investigational Site
Šahy, , Slovakia
Novo Nordisk Investigational Site
Žilina, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008 Feb;25(2):152-6. doi: 10.1111/j.1464-5491.2007.02333.x. Epub 2008 Jan 14.
Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Buganova I, Madsbad S. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x. No abstract available.
Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19. No abstract available.
Horowitz M, Vilsboll T, Zdravkovic M, Hammer M, Madsbad S. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes Obes Metab. 2008 Jul;10(7):593-6. doi: 10.1111/j.1463-1326.2008.00861.x. Epub 2008 Apr 22. No abstract available.
Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN2211-1571
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.